Please provide your email address to receive an email when new articles are posted on . Oteseconazole, an investigational oral antifungal therapy, was shown to be safe and effective in the treatment ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved ibrexafungerp, an oral, non-azole antifungal drug, for reducing the number of recurrent ...

BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC.

Vulvovaginal candidiasis (VVC) arises when commensal Candida species, most often Candida albicans, breach the mucosal barrier and provoke a local immune reaction. The vaginal epithelium acts as a ...

DUBLIN--(BUSINESS WIRE)--The "Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Drug Class, By Route of Administration ...

Credit: Getty Images. The approval was based on data from three phase 3 trials, which included female patients aged 12 years and older with at least 3 episodes of acute VVC in the past 12 months. The ...

October 9, 2009 — Monthly cycle–dependent itraconazole is more effective than classic homeopathy for treating recurrent vulvovaginal candidiasis (RVVC), according to the results of a single-center, ...

Vulvovaginal candidiasis (VVC) is one of the most common gynaecological infections worldwide, affecting an estimated 75 percent of women at least once in their lifetime and up to 8 percent ...

The global Vulvovaginal Candidiasis Treatment Market is currently valued at US$ 1035 Million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in the ...

Clotrimazole 100 mg vaginal tablet Gyne-Lotrimin-7 7 days Clotrimazole 100 mg vaginal tablet Gyne-Lotrimin-7 3 days Clotrimazole 500 mg vaginal tablet Gyne-Lotrimin single dose Miconazole 2% cream ...